RiaSTAP Disease Interactions

Thrombotic events have been reported in patients receiving human fibrinogen concentrate. Treatment with human fibrinogen concentrate has been associated with risk of thrombosis at target fibrinogen levels that were less than 150 mg/dL, and the risk may be greater when the target fibrinogen plasma level is 150 mg/dL. Weigh the benefits of fibrinogen administration versus the risks of thrombosis. Patients receiving fibrinogen should be monitored for signs and symptoms of thrombosis. Inform patients that blood clots with or without consequent obstruction of blood flow may occur and that any symptoms of blood clots (unexplained chest and/or leg pain or swelling of the legs or arms, coughing up blood, shortness of breath, increased rate of breathing or unexplained symptoms related to the nervous system such as stroke or weakness) should be reported to their physician immediately.